Leishmaniasis in immunosuppressed individuals

Clinical Microbiology and Infection

Volumn 20, Issue 4, 2014, Pages 286-299

  Van Griensven, J ^a   Carrillo, E ^b   Lopez Velez R ^c   Lynen, L ^a   Moreno, J ^b  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Anti TNF ; HIV; Immunosuppression; Leishmaniasis; Transplant; Visceral

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX;

CLINICAL FEATURE; DNA POLYMORPHISM; DRUG TREATMENT FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; INFECTION PREVENTION; INFECTION RISK; LABORATORY DIAGNOSIS; LEISHMANIASIS; MEDICAL CARE; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; SKIN LEISHMANIASIS; VISCERAL LEISHMANIASIS;

HUMAN IMMUNODEFICIENCY VIRUS; PROTOZOA;

ANTI-TNF-Α; HIV; IMMUNOSUPPRESSION; LEISHMANIASIS; TRANSPLANT; VISCERAL;

AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; HUMANS; IMMUNOCOMPROMISED HOST; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; RECURRENCE; TREATMENT OUTCOME; WORLD HEALTH;

EID: 84895925975     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12556     Document Type: Review

References (202)

1. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet 2005; 366: 1561-1577.
2. van Griensven J, Diro E. Visceral leishmaniasis. Infect Dis Clin North Am 2012; 26: 309-322.
3. Alvar J, Velez ID, Bern C et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012; 7: e35671.
4. Reithinger R, Dujardin JC, Louzir H et al. Cutaneous leishmaniasis. Lancet Infect Dis 2007; 7: 581-596.
5. Goto H, Lindoso JA. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther 2010; 8: 419-433.
6. Strazzulla A, Cocuzza S, Pinzone MR et al. Mucosal leishmaniasis: an underestimated presentation of a neglected disease. Biomed Res Int 2013; 2013: 805108.
7. Pavli A, Maltezou HC. Leishmaniasis, an emerging infection in travelers. Int J Infect Dis 2010; 14: e1032-e1039.
8. Bart A, van Thiel PP, de Vries HJ, Hodiamont CJ, Van Gool T. Imported leishmaniasis in the Netherlands from 2005 to 2012: epidemiology, diagnostic techniques and sequence-based species typing from 195 patients. Euro Surveill 2013; 18: 20544.
9. Gautret P, Cramer JP, Field V et al. Infectious diseases among travellers and migrants in Europe, EuroTravNet 2010. Euro Surveill 2012; 17: pii:20205.
10. Flores-Figueroa J, Okhuysen PC, von Sonnenburg F et al. Patterns of illness in travelers visiting Mexico and Central America: the GeoSentinel experience. Clin Infect Dis 2011; 53: 523-531.
11. Perez-Ayala A, Norman F, Perez-Molina JA et al. Imported leishmaniasis: a heterogeneous group of diseases. J Travel Med 2009; 16: 395-401.
12. Buonomano R, Brinkmann F, Leupin N et al. Holiday souvenirs from the Mediterranean: three instructive cases of visceral leishmaniasis. Scand J Infect Dis 2009; 41: 777-781.
13. Arce A, Estirado A, Ordobas M et al. Re-emergence of leishmaniasis in Spain: community outbreak in Madrid, Spain, 2009 to 2012. Euro Surveill 2013; 18: 20546.
14. Ready PD. Leishmaniasis emergence in Europe. Euro Surveill 2010; 15: 19505.
15. Dujardin JC, Campino L, Canavate C et al. Spread of vector-borne diseases and neglect of leishmaniasis, Europe. Emerg Infect Dis 2008; 14: 1013-1018.
16. Desjeux P, Alvar J. Leishmania/HIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol 2003; 97(suppl 1): 3-15.
17. Alvar J, Canavate C, Gutierrez-Solar B et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 1997; 10: 298-319.
18. Alvar J, Aparicio P, Aseffa A et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 2008; 21: 334-359, table of contents.
19. Lopez-Velez R, Casado JL, Pintado V. Decline of a visceral leishmaniasis epidemic in HIV-infected patients after the introduction of highly active antiretroviral therapy (HAART). Clin Microbiol Infect 2001; 7: 394-395.
20. Rabello A, Orsini M, Disch J. Leishmania/HIV co-infection in Brazil: an appraisal. Ann Trop Med Parasitol 2003; 97(suppl 1): 17-28.
21. Orsini M, Canela JR, Disch J et al. High frequency of asymptomatic Leishmania spp. infection among HIV-infected patients living in endemic areas for visceral leishmaniasis in Brazil. Trans R Soc Trop Med Hyg 2012; 106: 283-288.
22. Nascimento ET, Moura ML, Queiroz JW et al. The emergence of concurrent HIV-1/AIDS and visceral leishmaniasis in Northeast Brazil. Trans R Soc Trop Med Hyg 2011; 105: 298-300.
23. Alexandrino-de-Oliveira P, Santos-Oliveira JR, Dorval ME et al. HIV/AIDS-associated visceral leishmaniasis in patients from an endemic area in Central-west Brazil. Mem Inst Oswaldo Cruz 2010; 105: 692-697.
24. Jimenez MI, Lopez-Velez R, Molina R, Canavate C, Alvar J. HIV co-infection with a currently non-pathogenic flagellate. Lancet 1996; 347: 264-265.
25. Pacheco RS, Marzochi MC, Pires MQ et al. Parasite genotypically related to a monoxenous trypanosomatid of dog's flea causing opportunistic infection in an HIV positive patient. Mem Inst Oswaldo Cruz 1998; 93: 531-537.
26. Gramiccia M, Scalone A, Di Muccio T et al. The burden of visceral leishmaniasis in Italy from 1982 to 2012: a retrospective analysis of the multi-annual epidemic that occurred from 1989 to 2009. Euro Surveill 2013; 18: 20535.
27. Alves da Silva A, Pacheco-Silva A, de Castro Cintra Sesso R et al. The risk factors for and effects of visceral leishmaniasis in graft and renal transplant recipients. Transplantation 2013; 95: 721-727.
28. Veroux M, Corona D, Giuffrida G et al. Visceral leishmaniasis in the early post-transplant period after kidney transplantation: clinical features and therapeutic management. Transpl Infect Dis 2010; 12: 387-391.
29. Postorino MC, Bellantoni M, Catalano C et al. Visceral leishmaniasis reactivation in transplant patients: a minireview with report of a new case. J Nephrol 2011; 24: 530-534.
30. Campos-Varela I, Len O, Castells L et al. Visceral leishmaniasis among liver transplant recipients: an overview. Liver Transpl 2008; 14: 1816-1819.
31. Antinori S, Cascio A, Parravicini C, Bianchi R, Corbellino M. Leishmaniasis among organ transplant recipients. Lancet Infect Dis 2008; 8: 191-199.
32. Simon I, Wissing KM, Del Marmol V et al. Recurrent leishmaniasis in kidney transplant recipients: report of 2 cases and systematic review of the literature. Transpl Infect Dis 2011; 13: 397-406.
33. Roustan G, Jimenez JA, Gutierrez-Solar B et al. Post-kala-azar dermal leishmaniasis with mucosal involvement in a kidney transplant recipient: treatment with liposomal amphotericin B. Br J Dermatol 1998; 138: 526-528.
34. Ozcan D, Seckin D, Allahverdiyev AM et al. Liver transplant recipient with concomitant cutaneous and visceral leishmaniasis. Pediatr Transplant 2007; 11: 228-232.
35. Gontijo CM, Pacheco RS, Orefice F et al. Concurrent cutaneous, visceral and ocular leishmaniasis caused by Leishmania (Viannia) braziliensis in a kidney transplant patient. Mem Inst Oswaldo Cruz 2002; 97: 751-753.
36. Bouchekoua M, Trabelsi S, Ben Abdallah T, Khaled S. Visceral leishmaniasis after kidney transplantation: report of a new case and a review of the literature. Transplant Rev (Orlando) 2014; 28: 32-35.
37. Sirvent-von Bueltzingsloewen A, Marty P, Rosenthal E et al. Visceral leishmaniasis: a new opportunistic infection in hematopoietic stem-cell-transplanted patients. Bone Marrow Transplant 2004; 33: 667-668.
38. Agteresch HJ, Van 't Veer MB, Cornelissen JJ, Sluiters JF. Visceral leishmaniasis after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 40: 391-393.
39. Rodriguez-Wilhelmi P, Panizo C, Ruza E, Rocha E. Treatment of visceral leishmaniasis with liposomal amphotericin B in three immunocompromised patients. Med Clin (Barc) 2001; 116: 37-38.
40. Bautista G, Ramos A, Gil S. Visceral leishmaniasis in hematopoietic stem cell transplantation. Transpl Int 2012; 25: e83-e85.
41. Batista MV, Pierrotti LC, Abdala E et al. Endemic and opportunistic infections in Brazilian solid organ transplant recipients. Trop Med Int Health 2011; 16: 1134-1142.
42. Machado CM, Martins TC, Colturato I et al. Epidemiology of neglected tropical diseases in transplant recipients. Review of the literature and experience of a Brazilian HSCT center. Rev Inst Med Trop Sao Paulo 2009; 51: 309-324.
43. Ossandon A, Bompane D, Alessandri C et al. Leishmania in SLE mimicking an exacerbation. Clin Exp Rheumatol 2006; 24: 186-190.
44. Viana RB, Neiva CL, Dias AF, do Rosarioe Souza EJ, de Padua PM. Felty's syndrome and Kala-azar: a challenge for the rheumatologist. Rev Bras Reumatol 2010; 50: 710-713.
45. Castellino G, Govoni M, Trotta F. Comment on 'Leishmania in SLE mimicking and exacerbation'. Clin Exp Rheumatol 2007; 25: 661; author reply 661.
46. Erre GL, Mesina P, Tonelli N, Passiu G. Visceral leishmaniasis among immunosuppressed patients with rheumatic diseases. Clin Exp Rheumatol 2010; 28: 590-591.
47. Kritikos K, Haritatos E, Tsigkos S et al. An atypical presentation of visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with infliximab. J Clin Rheumatol 2010; 16: 38-39.
48. Sollima S, Corbellino M, Piolini R et al. Visceral leishmaniasis in a patient with Wegener's granulomatosis. Rheumatology (Oxford) 2004; 43: 935-937.
49. Arlet JB, Capron L, Pouchot J. Visceral leishmaniasis mimicking systemic lupus erythematosus. J Clin Rheumatol 2010; 16: 203-204.
50. Bogdan C. Leishmaniasis in rheumatology, haematology and oncology: epidemiological, immunological and clinical aspects and caveats. Ann Rheum Dis 2012; 71(suppl 2): i60-i66.
51. Zanger P, Kotter I, Kremsner PG, Gabrysch S. Tumor necrosis factor alpha antagonist drugs and leishmaniasis in Europe. Clin Microbiol Infect 2012; 18: 670-676.
52. Guedes-Barbosa LS, Pereira da Costa I, Fernandes V et al. Leishmaniasis during anti-tumor necrosis factor therapy: report of 4 cases and review of the literature (additional 28 cases). Semin Arthritis Rheum 2013; 43: 152-157.
53. Garcia-Gonzalez E, Guidelli GM, Bardelli M, Maggio R. Mucocutaneous leishmaniasis in a patient treated with anti-TNF-alpha therapy. Rheumatology (Oxford) 2012; 51: 1517-1518.
54. Gomes KW, Benevides AN, Vieira FJ et al. Cutaneous leishmaniasis in a patient with ankylosing spondylitis using adalimumab. Rev Bras Reumatol 2012; 52: 447-452.
55. Zanger P, Gabrysch S. Leishmaniasis in the era of tumor necrosis factor alpha antagonist therapy-a research agenda for Europe. Euro Surveill 2013; 18: 20542.
56. Pittalis S, Nicastri E, Spinazzola F et al. Leishmania infantum leishmaniasis in corticosteroid-treated patients. BMC Infect Dis 2006; 6: 177.
57. Chianura L, Cirasino L. Leishmania infection in a 51-year-old woman with sarcoidosis: case report. APMIS 2006; 114: 825-827.
58. Garcia-Cordoba F, Ortuno FJ, Segovia M, Gonzalez Diaz G. Fatal visceral leishmaniasis, with massive bone-marrow infection, in an immunosuppressed but HIV-negative Spanish patient, after the initiation of treatment with meglumine antimoniate. Ann Trop Med Parasitol 2005; 99: 125-130.
59. Hagenah GC, Wundisch T, Eckstein E et al. Sepsis-like disease in an immunocompromised patient with a travel history to Mallorca. Internist (Berl) 2007; 48: 727-730.
60. Casabianca A, Marchetti M, Zallio F et al. Seronegative visceral leishmaniasis with relapsing and fatal course following rituximab treatment. Infection 2011; 39: 375-378.
61. Kopterides P, Mourtzoukou EG, Skopelitis E, Tsavaris N, Falagas ME. Aspects of the association between leishmaniasis and malignant disorders. Trans R Soc Trop Med Hyg 2007; 101: 1181-1189.
62. Nylen S, Sacks D. Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol 2007; 28: 378-384.
63. Kaye P, Scott P. Leishmaniasis: complexity at the host-pathogen interface. Nat Rev Microbiol 2011; 9: 604-615.
64. McCall LI, Zhang WW, Matlashewski G. Determinants for the development of visceral leishmaniasis disease. PLoS Pathog 2013; 9: e1003053.
65. Michel G, Pomares C, Ferrua B, Marty P. Importance of worldwide asymptomatic carriers of Leishmania infantum (L. chagasi) in human. Acta Trop 2011; 119: 69-75.
66. Saporito L, Giammanco GM, De Grazia S, Colomba C. Visceral leishmaniasis: host-parasite interactions and clinical presentation in the immunocompetent and in the immunocompromised host. Int J Infect Dis 2013; 17: e572-e576.
67. Bogdan C. Mechanisms and consequences of persistence of intracellular pathogens: leishmaniasis as an example. Cell Microbiol 2008; 10: 1221-1234.
68. Ortiz AM, Silvestri G. Immunopathogenesis of AIDS. Curr Infect Dis Rep 2009; 11: 239-245.
69. Andreani G, Lodge R, Richard D, Tremblay MJ. Mechanisms of interaction between protozoan parasites and HIV. Curr Opin HIV AIDS 2012; 7: 276-282.
70. Santos-Oliveira JR, Giacoia-Gripp CB, Alexandrino de Oliveira P et al. High levels of T lymphocyte activation in Leishmania-HIV-1 co-infected individuals despite low HIV viral load. BMC Infect Dis 2010; 10: 358.
71. Santos-Oliveira JR, Regis EG, Leal CR et al. Evidence that lipopolysaccharide may contribute to the cytokine storm and cellular activation in patients with visceral leishmaniasis. PLoS Negl Trop Dis 2011; 5: e1198.
72. Santos-Oliveira JR, Regis EG, Giacoia-Gripp CB et al. Microbial translocation induces an intense proinflammatory response in patients with visceral leishmaniasis and HIV type 1 coinfection. J Infect Dis 2013; 208: 57-66.
73. Chinen J, Buckley RH. Transplantation immunology: solid organ and bone marrow. J Allergy Clin Immunol 2010; 125: S324-S335.
74. Martin-Davila P, Fortun J, Lopez-Velez R et al. Transmission of tropical and geographically restricted infections during solid-organ transplantation. Clin Microbiol Rev 2008; 21: 60-96.
75. Coster LO. Parasitic infections in solid organ transplant recipients. Infect Dis Clin North Am 2013; 27: 395-427.
76. Puig L, Pradinaud R. Leishmania and HIV co-infection: dermatological manifestations. Ann Trop Med Parasitol 2003; 97(suppl 1): 107-114.
77. Colebunders R, Depraetere K, Verstraeten T et al. Unusual cutaneous lesions in two patients with visceral leishmaniasis and HIV infection. J Am Acad Dermatol 1999; 41: 847-850.
78. Catorze G, Alberto J, Afonso A et al. Leishmania infantum/HIV co-infection: cutaneous lesions following treatment of visceral leishmaniasis. Ann Dermatol Venereol 2006; 133: 39-42.
79. Gonzalez-Beato MJ, Moyano B, Sanchez C et al. Kaposi's sarcoma-like lesions and other nodules as cutaneous involvement in AIDS-related visceral leishmaniasis. Br J Dermatol 2000; 143: 1316-1318.
80. Jeziorski E, Blanchet C, Ludwig C et al. Pseudotumoral-like recurrence of visceral leishmaniasis in a seven-year-old girl. Arch Pediatr 2009; 16(suppl 2): S129-S131.
81. Ara M, Maillo C, Peon G et al. Visceral leishmaniasis with cutaneous lesions in a patient infected with human immunodeficiency virus. Br J Dermatol 1998; 139: 114-117.
82. Perrin C, Taillan B, Hofman P et al. Atypical cutaneous histological features of visceral leishmaniasis in acquired immunodeficiency syndrome. Am J Dermatopathol 1995; 17: 145-150.
83. Alsina-Gibert M, Lopez-Lerma I, Martinez-Chamorro E, Herrero-Mateu C. Cutaneous manifestations of visceral leishmaniasis resistant to liposomal amphotericin B in an HIV-positive patient. Arch Dermatol 2006; 142: 787-789.
84. Bosch RJ, Rodrigo AB, Sanchez P, de Galvez MV, Herrera E. Presence of Leishmania organisms in specific and non-specific skin lesions in HIV-infected individuals with visceral leishmaniasis. Int J Dermatol 2002; 41: 670-675.
85. Fernandez-Guerrero ML, Robles P, Rivas P et al. Visceral leishmaniasis in immunocompromised patients with and without AIDS: a comparison of clinical features and prognosis. Acta Trop 2004; 90: 11-16.
86. Ritmeijer K, Veeken H, Melaku Y et al. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Trans R Soc Trop Med Hyg 2001; 95: 668-672.
87. Gilad J, Borer A, Hallel-Halevy D et al. Post-kala-azar dermal leishmaniasis manifesting after initiation of highly active anti-retroviral therapy in a patient with human immunodeficiency virus infection. Isr Med Assoc J 2001; 3: 451-452.
88. Farooq U, Choudhary S, Chacon AH et al. Post-kala-azar dermal leishmaniasis in HIV-infected patients with AIDS: a report of two cases diagnosed in the USA. Int J Dermatol 2013; 52: 1098-1104.
89. Ridolfo AL, Gervasoni C, Antinori S et al. Post-kala-azar dermal leishmaniasis during highly active antiretroviral therapy in an AIDS patient infected with Leishmania infantum. J Infect 2000; 40: 199-202.
90. Bittencourt A, Silva N, Straatmann A et al. Post-kala-azar dermal leishmaniasis associated with AIDS. Braz J Infect Dis 2002; 6: 313-316.
91. Rihl M, Stoll M, Ulbricht K, Bange FC, Schmidt RE. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe. J Infect 2006; 53: e25-e27.
92. Stark D, Pett S, Marriott D, Harkness J. Post-kala-azar dermal leishmaniasis due to Leishmania infantum in a human immunodeficiency virus type 1-infected patient. J Clin Microbiol 2006; 44: 1178-1180.
93. Sakkas LI, Boulbou M, Kyriakou D et al. Immunological features of visceral leishmaniasis may mimic systemic lupus erythematosus. Clin Biochem 2008; 41: 65-68.
94. Atta AM, Carvalho EM, Jeronimo SM, Sousa Atta ML. Serum markers of rheumatoid arthritis in visceral leishmaniasis: rheumatoid factor and anti-cyclic citrullinated peptide antibody. J Autoimmun 2007; 28: 55-58.
95. Rizos E, Dimos G, Liberopoulos EN, Elisaf MS, Drosos AA. Cryoglobulinemic purpura in visceral leishmaniasis. Rheumatol Int 2005; 25: 469-471.
96. Casato M, de Rosa FG, Pucillo LP et al. Mixed cryoglobulinemia secondary to visceral leishmaniasis. Arthritis Rheum 1999; 42: 2007-2011.
97. Voulgari PV, Pappas GA, Liberopoulos EN et al. Visceral leishmaniasis resembling systemic lupus erythematosus. Ann Rheum Dis 2004; 63: 1348-1349.
98. Venizelos I, Tatsiou Z, Papathomas TG, Orazi A. Visceral leishmaniasis in a rheumatoid arthritis patient treated with methotrexate. Int J Infect Dis 2009; 13: e169-e172.
99. Braun J, Sieper J, Schulte KL, Thiel E, Janitschke K. Visceral leishmaniasis mimicking a flare of systemic lupus erythematosus. Clin Rheumatol 1991; 10: 445-448.
100. Tunccan OG, Tufan A, Telli G et al. Visceral leishmaniasis mimicking autoimmune hepatitis, primary biliary cirrhosis, and systemic lupus erythematosus overlap. Korean J Parasitol 2012; 50: 133-136.
101. Bassetti M, Pizzorni C, Gradoni L et al. Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with adalimumab. Rheumatology (Oxford) 2006; 45: 1446-1448.
102. Williams VL, Cohen PR. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int J Dermatol 2011; 50: 619-625.
103. Kawakami A, Fukunaga T, Usui M et al. Visceral leishmaniasis misdiagnosed as malignant lymphoma. Intern Med 1996; 35: 502-506.
104. Jones SG, Forman KM, Clark D, Myers B. Visceral leishmaniasis misdiagnosed as probable acute lymphoblastic leukaemia. Hosp Med 2003; 64: 308-309.
105. Gagnaire MH, Galambrun C, Stephan JL. Hemophagocytic syndrome: a misleading complication of visceral leishmaniasis in children-a series of 12 cases. Pediatrics 2000; 106: E58.
106. Rajagopala S, Dutta U, Chandra KS et al. Visceral leishmaniasis associated hemophagocytic lymphohistiocytosis-case report and systematic review. J Infect 2008; 56: 381-388.
107. Randi ML, Ruzzon E, Tezza F, Pacquola E, Fabris F. Monoclonal gammopathy in human leishmaniasis. Neth J Med 2006; 64: 50-51.
108. Dalgic B, Dursun I, Akyol G. A case of visceral leishmaniasis misdiagnosed as autoimmune hepatitis. Turk J Gastroenterol 2005; 16: 52-53.
109. Makaritsis KP, Gatselis NK, Ioannou M, Petinaki E, Dalekos GN. Polyclonal hypergammaglobulinemia and high smooth-muscle autoantibody titers with specificity against filamentous actin: consider visceral leishmaniasis, not just autoimmune hepatitis. Int J Infect Dis 2009; 13: e157-e160.
110. De Leonardis F, Govoni M, Lo Monaco A, Trotta F. Visceral leishmaniasis and anti-TNF-alpha therapy: case report and review of the literature. Clin Exp Rheumatol 2009; 27: 503-506.
111. Besada E, Njalla RJ, Nossent JC. Imported case of visceral leishmaniasis presenting as pancytopenia in a Norwegian patient treated with methotrexate and etanercept for psoriasis arthritis. Rheumatol Int 2013; 33: 2687-2689.
112. Ates SC, Bagirova M, Allahverdiyev AM, Kocazeybek B, Kosan E. Utility of the microculture method for Leishmania detection in non-invasive samples obtained from a blood bank. Acta Trop 2013; 128: 54-60.
113. Lopez-Velez R, Laguna F, Alvar J et al. Parasitic culture of buffy coat for diagnosis of visceral leishmaniasis in human immunodeficiency virus-infected patients. J Clin Microbiol 1995; 33: 937-939.
114. Fillola G, Corberand JX, Laharrague PF et al. Peripheral intramonocytic leishmanias in an AIDS patient. J Clin Microbiol 1992; 30: 3284-3285.
115. Cruz I, Chicharro C, Nieto J et al. Comparison of new diagnostic tools for management of pediatric Mediterranean visceral leishmaniasis. J Clin Microbiol 2006; 44: 2343-2347.
116. Medrano FJ, Canavate C, Leal M et al. The role of serology in the diagnosis and prognosis of visceral leishmaniasis in patients coinfected with human immunodeficiency virus type-1. Am J Trop Med Hyg 1998; 59: 155-162.
117. Mary C, Lamouroux D, Dunan S, Quilici M. Western blot analysis of antibodies to Leishmania infantum antigens: potential of the 14-kD and 16-kD antigens for diagnosis and epidemiologic purposes. Am J Trop Med Hyg 1992; 47: 764-771.
118. Cota GF, de Sousa MR, Demarqui FN, Rabello A. The diagnostic accuracy of serologic and molecular methods for detecting visceral leishmaniasis in HIV infected patients: meta-analysis. PLoS Negl Trop Dis 2012; 6: e1665.
119. Molina I, Fisa R, Riera C et al. Ultrasensitive real-time PCR for the clinical management of visceral leishmaniasis in HIV-infected patients. Am J Trop Med Hyg 2013; 89: 105-110.
120. Bossolasco S, Gaiera G, Olchini D et al. Real-time PCR assay for clinical management of human immunodeficiency virus-infected patients with visceral leishmaniasis. J Clin Microbiol 2003; 41: 5080-5084.
121. Antinori S, Calattini S, Longhi E et al. Clinical use of polymerase chain reaction performed on peripheral blood and bone marrow samples for the diagnosis and monitoring of visceral leishmaniasis in HIV-infected and HIV-uninfected patients: a single-center, 8-year experience in Italy and review of the literature. Clin Infect Dis 2007; 44: 1602-1610.
122. Cruz I, Canavate C, Rubio JM et al. A nested polymerase chain reaction (Ln-PCR) for diagnosing and monitoring Leishmania infantum infection in patients co-infected with human immunodeficiency virus. Trans R Soc Trop Med Hyg 2002; 96(suppl 1): S185-S189.
123. Boelaert M, El-Safi S, Hailu A et al. Diagnostic tests for kala-azar: a multi-centre study of the freeze-dried DAT, rK39 strip test and KAtex in East Africa and the Indian subcontinent. Trans R Soc Trop Med Hyg 2008; 102: 32-40.
124. Riera C, Fisa R, Lopez P et al. Evaluation of a latex agglutination test (KAtex) for detection of Leishmania antigen in urine of patients with HIV-Leishmania coinfection: value in diagnosis and post-treatment follow-up. Eur J Clin Microbiol Infect Dis 2004; 23: 899-904.
125. Murray HW. Leishmaniasis in the United States: treatment in 2012. Am J Trop Med Hyg 2012; 86: 434-440.
126. Meyerhoff AUS. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 1999; 28: 42-48; discussion 49-51.
127. World Health Organization. Control of the leishmaniasis. Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22-26 March 2010. WHO technical report series 949 (2010). Geneva: WHO, 2010.
128. Panel on Opportunistic Infections in HIV-infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents:recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America (2013).
129. Sinha PK, van Griensven J, Pandey K et al. Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India. Clin Infect Dis 2011; 53: e91-e98.
130. Ritmeijer K, Dejenie A, Assefa Y et al. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis 2006; 43: 357-364.
131. Sindermann H, Engel KR, Fischer C, Bommer W. Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clin Infect Dis 2004; 39: 1520-1523.
132. Marques N, Sa R, Coelho F et al. Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients. Scand J Infect Dis 2008; 40: 523-526.
133. Troya J, Casquero A, Refoyo E, Fernandez-Guerrero ML, Gorgolas M. Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients. Scand J Infect Dis 2008; 40: 78-80.
134. van Griensven J, Balasegaram M, Meheus F et al. Combination therapy for visceral leishmaniasis. Lancet Infect Dis 2010; 10: 184-194.
135. van Griensven J, Diro E, Lopez-Velez R et al. HIV-1 protease inhibitors for treatment of visceral leishmaniasis in HIV-co-infected individuals. Lancet Infect Dis 2013; 13: 251-259.
136. Lawn SD, Wilkinson RJ. Immune reconstitution disease associated with parasitic infections following antiretroviral treatment. Parasite Immunol 2006; 28: 625-633.
137. ter Horst R, Collin SM, Ritmeijer K, Bogale A, Davidson RN. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis 2008; 46: 1702-1709.
138. Cota GF, de Sousa MR, Rabello A. Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review. PLoS Negl Trop Dis 2011; 5: e1153.
139. Barragan P, Lopez-Velez R, Olmo M, Podzamczer D. Visceral leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient. Am J Trop Med Hyg 2010; 83: 10-12.
140. Lopez-Velez R, Videla S, Marquez M et al. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 2004; 53: 540-543.
141. Schwartz BS, Mawhorter SD. Parasitic infections in solid organ transplantation. Am J Transplant 2013; 13(suppl 4): 280-303.
142. Llorente S, Gimeno L, Navarro MJ, Moreno S, Rodriguez-Girones M. Therapy of visceral leishmaniasis in renal transplant recipients intolerant to pentavalent antimonials. Transplantation 2000; 70: 800-801.
143. Torrus D, Boix V, Massa B, Portilla J, Perez-Mateo M. Fluconazole plus allopurinol in treatment of visceral leishmaniasis. J Antimicrob Chemother 1996; 37: 1042-1043.
144. Halim MA, Alfurayh O, Kalin ME et al. Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in a renal transplant recipient after the occurrence of pancreatitis due to stibogluconate. Clin Infect Dis 1993; 16: 397-399.
145. Hueso M, Bover J, Seron D et al. The renal transplant patient with visceral leishmaniasis who could not tolerate meglumine antimoniate-cure with ketoconazole and allopurinol. Nephrol Dial Transplant 1999; 14: 2941-2943.
146. Moreno D, Martinez P, Berbegal J, Femenia M. Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with adalimumab: a case description and literature review. Enferm Infecc Microbiol Clin 2010; 28: 261-262.
147. Len O, Gavalda J, Blanes M et al. Donor infection and transmission to the recipient of a solid allograft. Am J Transplant 2008; 8: 2420-2425.
148. Cascio A, Iaria C. Appropriate screening for leishmaniasis before immunosuppressive treatments. Emerg Infect Dis 2009; 15: 1706; author reply 1706-1707.
149. Xynos ID, Tektonidou MG, Pikazis D, Sipsas NV. Leishmaniasis, autoimmune rheumatic disease, and anti-tumor necrosis factor therapy, Europe. Emerg Infect Dis 2009; 15: 956-959.
150. Garcia-Vidal C, Rodriguez-Fernandez S, Teijon S et al. Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention. Eur J Clin Microbiol Infect Dis 2009; 28: 331-337.
151. Fitzpatrick MA, Caicedo JC, Stosor V, Ison MG. Expanded infectious diseases screening program for Hispanic transplant candidates. Transpl Infect Dis 2010; 12: 336-341.
152. Alimohammadian MH, Jones SL, Darabi H et al. Assessment of interferon-gamma levels and leishmanin skin test results in persons recovered for leishmaniasis. Am J Trop Med Hyg 2012; 87: 70-75.
153. Gidwani K, Jones S, Kumar R, Boelaert M, Sundar S. Interferon-gamma release assay (modified QuantiFERON) as a potential marker of infection for Leishmania donovani, a proof of concept study. PLoS Negl Trop Dis 2011; 5: e1042.
154. Turgay N, Balcioglu IC, Toz SO, Ozbel Y, Jones SL. Quantiferon-Leishmania as an epidemiological tool for evaluating the exposure to Leishmania infection. Am J Trop Med Hyg 2010; 83: 822-824.
155. Saidenberg-Kermanac'h N, Semerano L, Naccache JM et al. Screening for latent tuberculosis in anti-TNF-alpha candidate patients in a high tuberculosis incidence setting. Int J Tuberc Lung Dis 2012; 16: 1307-1314.
156. Horne DJ, Narita M, Spitters CL et al. Challenging issues in tuberculosis in solid organ transplantation. Clin Infect Dis 2013; 57: 1473-1482.
157. Altclas J, Sinagra A, Dictar M et al. Chagas disease in bone marrow transplantation: an approach to preemptive therapy. Bone Marrow Transplant 2005; 36: 123-129.
158. Clemente WT, Rabello A, Faria LC et al. High prevalence of asymptomatic Leishmania spp. infection among liver transplant recipients and donors from an endemic area of Brazil. Am J Transplant 2014; 14: 96-101.
159. Guiguemde RT, Sawadogo OS, Bories C et al. Leishmania major and HIV co-infection in Burkina Faso. Trans R Soc Trop Med Hyg 2003; 97: 168-169.
160. Zandieh A, Zandieh B, Dastgheib L. Dissemination of localized cutaneous leishmaniasis in an organ transplant recipient: case report and literature review. Int J Dermatol 2013; 52: 59-62.
161. Vinhal FA, Afonso-Cardoso SR, Silva AG et al. A typical presentation of cutaneous leishmaniasis after renal transplantation. Nephrol Dial Transplant 2007; 22: 3674.
162. Yaich S, Charfeddine K, Masmoudi A et al. Atypical presentation of cutaneous leishmaniasis in a renal transplant recipient successfully treated with allopurinol and fluconazole. Ann Saudi Med 2013; 33: 187-191.
163. Neumayr AL, Morizot G, Visser LG et al. Clinical aspects and management of cutaneous leishmaniasis in rheumatoid patients treated with TNF-alpha antagonists. Travel Med Infect Dis 2013; 11: 412-420.
164. Romero-Mate A, Martinez-Sanchez D, Tardio JC et al. Cutaneous leishmaniasis with histopathologic pattern of non-necrotizing granulomatous dermatitis in patients treated with adalimumab. Dermatol Online J 2012; 18: 7.
165. Hakimi S, Riviere S, Del Giudice P, Dereure J, Le Quellec A. Localized cutaneous leishmaniasis due to Leishmania infantum in a patient treated with infliximab. Dermatology 2010; 220: 63-65.
166. Hernandez-Torres A, Garcia-Vazquez E, Frias-Iniesta J, Herrero-Martinez JA, Gomez-Gomez J. Cutaneous leishmaniasis in a patient receiving infliximab. Scand J Infect Dis 2013; 45: 567-569.
167. Tuon FF, Sabbaga AmatoV, Floeter-Winter LM et al. Cutaneous leishmaniasis reactivation 2 years after treatment caused by systemic corticosteroids-first report. Int J Dermatol 2007; 46: 628-630.
168. Kerr A, Dawe RS, Nathwani D, Evans AT, Ferguson J. Presentation of leishmaniasis (Leishmania infantum) in the skin of a patient with severe atopic dermatitis. Br J Dermatol 2009; 161: 202-203.
169. Guerra JA, Coelho LI, Pereira FR et al. American tegumentary leishmaniasis and HIV-AIDS association in a tertiary care center in the Brazilian Amazon. Am J Trop Med Hyg 2011; 85: 524-527.
170. Lindoso JA, Barbosa RN, Posada-Vergara MP et al. Unusual manifestations of tegumentary leishmaniasis in AIDS patients from the New World. Br J Dermatol 2009; 160: 311-318.
171. Niamba P, Traore A, Goumbri-Lompo O et al. Cutaneous leishmania in HIV patient in Ouagadougou: clinical and therapeutic aspects. Ann Dermatol Venereol 2006; 133: 537-542.
172. Ndiaye PB, Develoux M, Dieng MT, Huerre M. Diffuse cutaneous leishmaniasis and acquired immunodeficiency syndrome in a Senegalese patient. Bull Soc Pathol Exot 1996; 89: 282-286.
173. Faucher B, Pomares C, Fourcade S et al. Mucosal Leishmania infantum leishmaniasis: specific pattern in a multicentre survey and historical cases. J Infect 2011; 63: 76-82.
174. Jafari S, Hajiabdolbaghi M, Mohebali M, Hajjaran H, Hashemian H. Disseminated leishmaniasis caused by Leishmania tropica in HIV-positive patients in the Islamic Republic of Iran. East Mediterr Health J 2010; 16: 340-343.
175. Alborzi A, Pouladfar GR, Fakhar M et al. Isolation of Leishmania tropica from a patient with visceral leishmaniasis and disseminated cutaneous leishmaniasis, southern Iran. Am J Trop Med Hyg 2008; 79: 435-437.
176. Posada-Vergara MP, Lindoso JA, Tolezano JE et al. Tegumentary leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome in 2 patients with AIDS. J Infect Dis 2005; 192: 1819-1822.
177. Blum JA, Hatz CF. Treatment of cutaneous leishmaniasis in travelers 2009. J Travel Med 2009; 16: 123-131.
178. Almeida OL, Santos JB. Advances in the treatment of cutaneous leishmaniasis in the new world in the last ten years: a systematic literature review. An Bras Dermatol 2011; 86: 497-506.
179. Gonzalez U, Pinart M, Reveiz L, Alvar J. Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev 2008: CD005067.
180. Gonzalez U, Pinart M, Rengifo-Pardo M et al. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev 2009: CD004834.
181. Monge-Maillo B, Lopez-Velez R. Therapeutic options for Old World cutaneous leishmaniasis and New World cutaneous and mucocutaneous leishmaniasis. Drugs 2013; 73: 1889-1920.
182. Aliaga L, Cobo F, Mediavilla JD et al. Localized mucosal leishmaniasis due to Leishmania (Leishmania) infantum: clinical and microbiologic findings in 31 patients. Medicine (Baltimore) 2003; 82: 147-158.
183. Martinez-Losada C, Martin C, Cuenca T, Torres A. Duodenal leishmaniasis after allogeneic hematopoietic SCT. Bone Marrow Transplant 2013; 48: 614-615.
184. Vargas Acosta AM, Belchi Segura E, Martinez Caselles A et al. Diarrhea due to visceral leishmaniasis in a liver transplant recipient. Gastroenterol Hepatol 2013; 36: 271-273.
185. Cuperus FC, Oosterwijk PR, Vos A et al. Visceral leishmaniasis: not only a tropical disease. Ned Tijdschr Geneeskd 2013; 157: A5958.
186. Berry CE, Tsai J, Tierney A, Pickles R. Visceral leishmaniasis in a patient taking adalimumab for rheumatoid arthritis. Med J Aust 2013; 198: 331-333.
187. Toqeer M, Rahman N, Whitehead MW, Lockwood D. Visceral leishmaniasis in immunosuppressed Caucasian patient. BMJ Case Rep 2012; 2012: pii: bcr1120115199.
188. Karagiannidis GS, Mantzourani M, Meletis J, Anastasopoulou AN, Vaiopoulos GA. Visceral leishmaniasis in a rheumatoid arthritis patient treated with methotrexate. J Clin Rheumatol 2012; 18: 59.
189. Guirao-Arrabal E, Garcia-Olid B, Munoz-Lopez C, Fernandez de la Puebla-Gimenez RA. Comment on ;visceral leishmaniasis in a rheumatoid arthritis patient treated with methotrexate'. J Clin Rheumatol 2013; 19: 165.
190. Bousquet E, Mura F, Villain M et al. Infectious complications in patients treated with anti-TNF-alpha: two cases of leishmaniasis. J Fr Ophtalmol 2012; 35: 695-699.
191. Khan A, Coakley G, Cosgrove C, Lockwood D. Let off the leash: kala-azar following the use of tumour necrosis factor antibodies. BMJ Case Rep 2010; 2010: pii: bcr0420102878.
192. Di Cataldo A, Lo Nigro L, Marino S, Schiliro G. Visceral leishmaniasis in three children with leukemia. Pediatr Infect Dis J 1996; 15: 916-918.
193. Nafil H, Tazi I, Mahmal L. Association of acute lymphoblastic leukaemia and visceral leishmaniasis. Ann Biol Clin (Paris) 2011; 69: 729-731.
194. Kapila K, Prakash MB, Mehrota R, Vermar K. Testicular leishmaniasis in a boy with acute lymphoblastic leukemia. Acta Cytol 1994; 38: 878-879.
195. Fernandez-Guerrero ML, Aguado JM, Buzon L et al. Visceral leishmaniasis in immunocompromised hosts. Am J Med 1987; 83: 1098-1102.
196. Chappuis F, Sundar S, Hailu A et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 2007; 5: 873-882.
197. Lima IP, Muller MC, Holanda TA et al. Human immunodeficiency virus/Leishmania infantum in the first foci of urban American visceral leishmaniasis: clinical presentation from 1994 to 2010. Rev Soc Bras Med Trop 2013; 46: 156-160.
198. Cota GF, de Sousa MR, de Freitas Nogueira BM et al. Comparison of parasitological, serological, and molecular tests for visceral leishmaniasis in HIV-infected patients: a cross-sectional delayed-type study. Am J Trop Med Hyg 2013; 89: 570-577.
199. Lachaud L, Dereure J, Chabbert E et al. Optimized PCR using patient blood samples for diagnosis and follow-up of visceral leishmaniasis, with special reference to AIDS patients. J Clin Microbiol 2000; 38: 236-240.
200. Campino L, Cortes S, Pires R, Oskam L, Abranches P. Detection of Leishmania in immunocompromised patients using peripheral blood spots on filter paper and the polymerase chain reaction. Eur J Clin Microbiol Infect Dis 2000; 19: 396-398.
201. Rijal S, Boelaert M, Regmi S et al. Evaluation of a urinary antigen-based latex agglutination test in the diagnosis of kala-azar in eastern Nepal. Trop Med Int Health 2004; 9: 724-729.
202. Chappuis F, Rijal S, Soto A, Menten J, Boelaert M. A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral leishmaniasis. BMJ 2006; 333: 723-726.